NEW YORK (360Dx) – OncoMark on Wednesday announced €2.1 million ($2.2 million) in funding to commercialize its breast cancer diagnostic test.

The Irish diagnostics firm plans to launch the test, called OncoMasTR, in 2018, it said. A biomarker-based prognostic test for early-stage breast cancer, OncoMasTR is aimed at reducing the number of patients who needlessly receive chemotherapy.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.